Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Human Interferon α1b Inhaled Solution for RSV Lower Respiratory Tract Infection in Children
NCT06363370Phase 3Recruiting
- Sponsor
- Kexing Biopharm
- Start
- Mar 2024
- Primary completion
- Jun 2027
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 3 trial of GB05 in respiratory syncytial virus infection (RSV), sponsored by Kexing Biopharm. Started Mar 2024; status: recruiting.
02
Drugs
GB05
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT06363370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06363370.